ArticleInternational journal of pharmaceutics: X2026
Lactoferrin-modified MSC-derived extracellular vesicles facilitate BBB penetration and enhance gastrodin-induced neuroprotection in Parkinson's disease: involvement of mitophagy.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The blood-brain barrier (BBB) severely impedes neuroprotective agent delivery to the brain in Parkinson's disease (PD). Although gastrodin (Gas) possesses neuroprotective properties, its efficacy is limited by poor BBB permeability. This study aimed to develop a brain-targeted extracellular vesicle (EV) delivery system for Gas and elucidate its neuroprotective mechanisms. Methods: A brain-targeted EV delivery system was developed using mesenchymal stem cell-derived EVs modified with lactoferrin (Lf). Gas was loaded into Lf-EVs via sonication to construct Lf-EVs-Gas nanocomplexes. The nanocomplexes were characterized by transmission electron microscopy, western blotting, and nano-flow cytometry. Results: Lf-EVs-Gas exhibited a typical cup-shaped morphology, with a mean size of 79.08 nm and a drug loading efficiency of 47.08 ± 4.63%. Lf functionalization significantly enhanced BBB transport, achieving a brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice versus undetectable levels for free Gas. The targeted system demonstrated superior brain accumulation versus non-targeted vesicles. In 6-OHDA-treated SH-SY5Y cells and MPTP-induced PD mice, the system upregulated tyrosine hydroxylase, reduced α-synuclein aggregation, inhibited neuronal apoptosis, and improved motor function. Mechanistically, these protective effects of Lf-EVs-Gas were associated with activation of PINK1-related mitophagy, as evidenced by elevated LC3-II/LC3-I ratio and increased TOMM20/LC3 colocalization. Conclusion: Lf-EVs-Gas enhanced the brain delivery of Gas and produced neuroprotective effects in cellular and mouse toxin-based models of PD. These effects were associated with the activation of PINK1-related mitophagy, supporting Lf-modified EVs as a promising brain-targeted delivery platform for Gas. Further studies establishing mechanistic causality, long-term safety, and efficacy in progressive PD models are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.